CareDx (CareDx) Debt-to-Equity

: 0.13 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

CareDx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.9 Mil. CareDx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $28.3 Mil. CareDx's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $261.3 Mil. CareDx's debt to equity for the quarter that ended in Dec. 2023 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CareDx's Debt-to-Equity or its related term are showing as below:

CDNA' s Debt-to-Equity Range Over the Past 10 Years
Min: -5.56 Med: 0.09 Max: 1.23
Current: 0.13

During the past 12 years, the highest Debt-to-Equity Ratio of CareDx was 1.23. The lowest was -5.56. And the median was 0.09.

CDNA's Debt-to-Equity is ranked better than
65.99% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.24 vs CDNA: 0.13

CareDx Debt-to-Equity Historical Data

The historical data trend for CareDx's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CareDx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.05

0.07

0.05

0.09

0.13

CareDx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.09	0.09	0.09	0.09	0.13

Competitive Comparison

For the Diagnostics & Research subindustry, CareDx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CareDx Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CareDx's Debt-to-Equity falls into.

CareDx Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CareDx's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.943	+	28.278)	/	261.328
	=	0.13

CareDx's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.943	+	28.278)	/	261.328
	=	0.13

CareDx (NAS:CDNA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CareDx Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CareDx's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CareDx (CareDx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CareDx Inc (NAS:CDNA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

1K9:Germany

Address

8000 Marina Boulevard, Brisbane, CA, USA, 94005

Website

https://www.caredx.com

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia and Stockholm, Sweden.

Executives

Reginald Seeto	officer: See Remarks	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Peter Maag	director, officer: President and CEO	CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Abraham Ronai	officer: See Remarks	C/O CAREDX, INC., 8000 MARINA BLVD, BRISBANE CA 94005
Grace Colon	director	C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Abhishek Jain	officer: See Remarks	C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Michael Goldberg	director	3000 SAND HILL ROAD, BUILDING 3, SUITE 290, MENLO PARK CA 94025
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Ankur Dhingra	officer: Chief Financial Officer	C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Arthur A Torres	director	87 BVENA VISTA TERRACE, SAN FRANCISCO CA 94117
Alexander L Johnson	officer: Chief Business Officer	C/O DIADEXUS, INC., 349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Sasha King	officer: Chief Commercial Officer	C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
William A Hagstrom	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Ralph Snyderman	director	C/O SAIC, 10260 CAMPUS POINT DR M/S F3, SAN DIEGO CA 92121
Marcel Konrad	officer: See Remarks	C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080